Incidence of <i>Saccharomyces cerevisiae</i> fungemia in hospitalised patients administered <i>Saccharomyces boulardii</i> probiotic

The risk of bloodstream infection as a result of S boulardii probiotic use appears restricted to S boulardii recipients. The risk for probiotic-related bloodstream infection does not appear greater than the risk of any hospital-acquired bloodstream infection both inside and outside of the intensive care unit.